Study on â??Vali Perunkazhichalâ?? (Diarrhoea) with the evaluation of trial drug â??Pirandai Uppuâ??

An open Pilot Clinical study on â??Vali Perunkazhichalâ?? (Diarrhoea) with the evaluation of trial drug â??Pirandai Uppuâ??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/08/004936

Enrollment

Registered

2014-08-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MALE AND FEMALE WITH DIARRHEA

Interventions

Intervention1: NIL: NIL Intervention2: PIRANDAI UPPU: DOSE 500 MG DURATION 5 DAYS bd ADJUVANT BUTTERMILK INDICATION DIARRHEA Control Intervention1: LOPERAMIDE 3 mg/kg OD: NIL Control Intervention2: N

Eligibility

Inclusion criteria

Inclusion criteria: Patients with appropriate symptoms like Diarrhoea may be accompanied by Cramping, abdominal pain, nausea, loss of bowel control. Non specific diarrhoea

Exclusion criteria

Exclusion criteria: Subjects below 12 years Pregnant and lactating womens History of Cholera History of Diverticulitis History of Bacterial dysentery History of Gastroenteritis History of crohnâ??s disease History of Colon carcinoma History of Amoebicdysentery

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by reduction in clinical symptoms and by comparing the following parameters before and after treatment. ï?? Changes in the faeces test Timepoint: 5 DAYS	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatment.Timepoint: 5 DAYS	—

Countries

India

Contacts

Public ContactPROF Dr P PARTHIBAN MD S

GOVERNMENT SIDDHA MEDICAL COLLEGE

drkkanakavalli@gmail.com9444122865

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026